FDA Approves Zynyz (retifanlimab-dlwr) for 1L Treatment of Advanced Anal Cancer Patients May 21, 2025
Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of R/R multiple myeloma May 21, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer patients May 13, 2025
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of R/R Multiple Myeloma May 6, 2025
MHRA grants conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with R/R B-ALL April 30, 2025
Ivonescimab Receives NMPA Approval for 1L Treatment of PD-L1-Positive NSCLC, Based on Ph 3 Trial Demonstrating Superior Efficacy Over Keytruda April 30, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in R/R multiple myeloma April 22, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
Enhertu approved in the EU for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy April 8, 2025
TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer April 2, 2025
FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic CRPC April 2, 2025
U.S. FDA Approves CABOMETYX for Patients with Previously Treated Advanced Neuroendocrine Tumors April 2, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with muscle-invasive bladder cancer April 2, 2025
